Mark Cicacci Email & Phone Number

Pennsylvania, United States

Pa, Ny, Nj, Oh

Pa, Oh, Ky, Ny, Wv, Va, Md

Hired to build Flexion's first sales team for launch of Zilretta, our first commercial product, a buy and bill injectable for OA knee pain. 2020 President Club Winner. Leading one of highest performing regions consistently ranked in top 3 in sales volume launch to date. Flexion was acquired 1/22

Providing direction on commercial strategy for company's preclinical rare disease product.

Greater Pittsburgh Area

Providing commercial build out strategy and support for emerging biopharma companies focused on bringing products for rare disease to market.• Conducting assessment of commercial opportunity of a pre-clinical compound for an early stage startup.• Assisting in the writing of the company’s S-1 for potential IPO Q2 2017 and creating the commercial strategy to support the launch of the company’s rare disease product in 2020

Eastern Us

Leading sales team responsible for Gattex,ultra rare disease biologic for short bowel syndrome in Eastern U.S. Charged with exceeding Shire corporate revenue targets and new patient adds for the Eastern U.S.

Eastern Us Maine To South Carolina

Responible for the build out of the NPS commercial sales team. Recruited and hired team of highly specialized Area Business Specialists for launch of ultra orphan disease injectible Gattex for Adult Short Bowel Patients dependent on parenteral support. Managing all aspects of commercial sales for Eastern United States.

Pa, Oh, Wv, Ny, Mi, Ky

Managing a team of highly specialized biologic sales representatives responsible for the promotion of the anti TNF Cimzia for rheumatoid arthritis. Skilled in buy and bill, specialty pharmacy and working with service center to facilitate processing of patient rx's and increased patient starts.

Eastern Us

Tx,Ok,Gulf Coast

Western Pa, West Virginia

Launched injectable biologics Rebif for relapsing MS In multi state territory.

Western Pa

Responsible for sales of Taxotere for metastatic breast and NSCL cancer as well as Anzemet for CINV. Prior experience selling Gliadel for recurrent glioblastoma.

Greater Pittsburgh Area

Launched block buster anti psychotic Zyprexa. $550m first year sales nationwide. Market leader in territory’s

Pennsylvania

Northeastern Pennsylvania